AlphaCentric Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

AlphaCentric Advisors’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$962K	Buy	137,000 +89,500	+188%	+$936K	0.28%	33
2021 Q3	$542K	Buy	+47,500	New	+$694K	0.14%	65
2021 Q1	–	Sell	-4,000	Closed	-$54K	–	227
2020 Q4	$54K	Buy	4,000 +3,900	+3,900%	+$47.1K	0.02%	178
2020 Q3	$1K	Buy	+100	New	+$1.22K	﹤0.01%	165

Other funds holding AERI

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

AlphaCentric Advisors's AERI Position: Q4 2021 in Review

AlphaCentric Advisors increased its Aerie Pharmaceuticals (AERI) stake by 188% in Q4 2021, buying an estimated $936K and bringing the position to 137,000 shares worth $962K. The position accounts for 0.28% of the portfolio, ranked #33.

AlphaCentric Advisors first reported a position in AERI in Q3 2020 and has held it in 4 quarters since. 129 funds tracked by Wall St. Rank hold AERI as of Q4 2021.

AlphaCentric Advisors held 137,000 shares of Aerie Pharmaceuticals worth $962K as of Q4 2021.
AlphaCentric Advisors bought 89,500 Aerie Pharmaceuticals shares in Q4 2021, an estimated $936K.
Aerie Pharmaceuticals made up 0.28% of AlphaCentric Advisors's portfolio in Q4 2021, its #33 holding.
AlphaCentric Advisors first reported a position in Aerie Pharmaceuticals in Q3 2020 and has held it in 4 quarters since.
129 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.